JP2023501853A - 経口gsnor阻害剤およびその医薬用途 - Google Patents
経口gsnor阻害剤およびその医薬用途 Download PDFInfo
- Publication number
- JP2023501853A JP2023501853A JP2022505579A JP2022505579A JP2023501853A JP 2023501853 A JP2023501853 A JP 2023501853A JP 2022505579 A JP2022505579 A JP 2022505579A JP 2022505579 A JP2022505579 A JP 2022505579A JP 2023501853 A JP2023501853 A JP 2023501853A
- Authority
- JP
- Japan
- Prior art keywords
- compounds
- present
- administration
- target compound
- aortic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100039702 Alcohol dehydrogenase class-3 Human genes 0.000 title abstract description 12
- 101000959452 Homo sapiens Alcohol dehydrogenase class-3 Proteins 0.000 title abstract description 12
- 239000003112 inhibitor Substances 0.000 title description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 27
- 208000002251 Dissecting Aneurysm Diseases 0.000 claims abstract description 22
- 206010002895 aortic dissection Diseases 0.000 claims abstract description 22
- 208000007474 aortic aneurysm Diseases 0.000 claims abstract description 20
- 201000009101 diabetic angiopathy Diseases 0.000 claims abstract description 19
- 201000010099 disease Diseases 0.000 claims abstract description 18
- 208000006673 asthma Diseases 0.000 claims abstract description 15
- 201000003883 Cystic fibrosis Diseases 0.000 claims abstract description 14
- IHDKBHLTKNUCCW-UHFFFAOYSA-N 1,3-thiazole 1-oxide Chemical class O=S1C=CN=C1 IHDKBHLTKNUCCW-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 23
- 210000002889 endothelial cell Anatomy 0.000 abstract description 14
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 13
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 13
- 239000008103 glucose Substances 0.000 abstract description 13
- 241000699670 Mus sp. Species 0.000 abstract description 11
- 150000001875 compounds Chemical class 0.000 abstract description 10
- 230000017531 blood circulation Effects 0.000 abstract description 7
- 102000005862 Angiotensin II Human genes 0.000 abstract description 6
- 101800000733 Angiotensin-2 Proteins 0.000 abstract description 6
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 abstract description 6
- 229950006323 angiotensin ii Drugs 0.000 abstract description 6
- 230000035699 permeability Effects 0.000 abstract description 6
- 210000000329 smooth muscle myocyte Anatomy 0.000 abstract description 5
- 230000033115 angiogenesis Effects 0.000 abstract description 4
- 230000000302 ischemic effect Effects 0.000 abstract description 4
- 238000011084 recovery Methods 0.000 abstract description 4
- 210000003606 umbilical vein Anatomy 0.000 abstract description 4
- 241001465754 Metazoa Species 0.000 abstract description 3
- 230000002829 reductive effect Effects 0.000 abstract description 3
- 238000012404 In vitro experiment Methods 0.000 abstract 3
- 230000001617 migratory effect Effects 0.000 abstract 1
- 229940125904 compound 1 Drugs 0.000 description 64
- 238000000338 in vitro Methods 0.000 description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000003304 gavage Methods 0.000 description 6
- 238000010253 intravenous injection Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 5
- AGSPXMVUFBBBMO-UHFFFAOYSA-N beta-aminopropionitrile Chemical compound NCCC#N AGSPXMVUFBBBMO-UHFFFAOYSA-N 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000003305 oral gavage Methods 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- HYHSBSXUHZOYLX-WDSKDSINSA-N S-nitrosoglutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CSN=O)C(=O)NCC(O)=O HYHSBSXUHZOYLX-WDSKDSINSA-N 0.000 description 4
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 4
- 210000002376 aorta thoracic Anatomy 0.000 description 4
- 238000013227 male C57BL/6J mice Methods 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 4
- 229960001052 streptozocin Drugs 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 230000002491 angiogenic effect Effects 0.000 description 3
- 210000000709 aorta Anatomy 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000005119 human aortic smooth muscle cell Anatomy 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 3
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 3
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- 230000001174 ascending effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 108091092328 cellular RNA Proteins 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 201000002818 limb ischemia Diseases 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- ABFPKTQEQNICFT-UHFFFAOYSA-M 2-chloro-1-methylpyridin-1-ium;iodide Chemical compound [I-].C[N+]1=CC=CC=C1Cl ABFPKTQEQNICFT-UHFFFAOYSA-M 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 102100025580 Calmodulin-1 Human genes 0.000 description 1
- 101710164735 Calmodulin-1 Proteins 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 206010048554 Endothelial dysfunction Diseases 0.000 description 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 description 1
- 101001139134 Homo sapiens Krueppel-like factor 4 Proteins 0.000 description 1
- 101001139130 Homo sapiens Krueppel-like factor 5 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102100020677 Krueppel-like factor 4 Human genes 0.000 description 1
- 102100020680 Krueppel-like factor 5 Human genes 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 208000001826 Marfan syndrome Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 102000004264 Osteopontin Human genes 0.000 description 1
- 108010081689 Osteopontin Proteins 0.000 description 1
- 206010034476 Pericardial haemorrhage Diseases 0.000 description 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
- 101710204736 Platelet endothelial cell adhesion molecule Proteins 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 206010049771 Shock haemorrhagic Diseases 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 102000003932 Transgelin Human genes 0.000 description 1
- 108090000333 Transgelin Proteins 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 101000678336 Xenopus laevis Actin, alpha skeletal muscle 2 Proteins 0.000 description 1
- 101000678338 Xenopus tropicalis Actin, alpha cardiac muscle 2 Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000037884 allergic airway inflammation Diseases 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000027746 artery morphogenesis Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000023819 chronic asthma Diseases 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000008694 endothelial dysfunction Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 230000004218 vascular function Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
250mlの一口フラスコに、3-(5-(4-(1H-イミダゾール-1-イル)フェニル)-1-(4-カルバモイル-2-メチルフェニル)-1H-ピロール-2-イル)プロピオン酸(N6022,500mg,1.21mmol)、2-クロロ-1-メチルピリジニウムヨージド(CMPI,370mg,1.45mmol)、ジメチルアミノピリジン(DMAP,10mg,0.06mmol)、チアゾリジノン(250mg,2.41mmol)、トリエチルアミン(TEA,490.2mg,4.84mmol)を順に仕込み、さらにジクロロメタン(15ml)を加え、室温で8時間反応させた。吸引濾過し、濾液を取り、希塩酸でpHを7に調整し、ジクロロメタン(15ml)、水(15ml)を加えて抽出し、有機相を合わせ、回転蒸発で乾燥させ、カラムクロマトグラフィー(ジクロロメタン:メタノール=25:1)にて分離することでベージュ色の粗製品400mgが得られ、無水メタノールで再結晶化して白色固体195mg(収率32%)が得られた。
1H NMR(クロロホルム-d,400MHz)δ(ppm):δ7.81-7.67(m,3H),7.39(d,J=7.6Hz,1H),7.30-7.10(m,2H),6.84(s,1H),6.40(s,1H),6.13(s,1H),4.06(s,2H),3.22(s,2H),3.02(s,2H),2.60(s,2H),1.82(s,3H).
GSNORは、喘息および嚢胞性線維症において非常に重要な調節役割を果たす。喘息患者の肺部ではGSNOR活性が顕著に高まり、GSNORの対立遺伝子の変異により小児が喘息に罹患する可能性が顕著に大きくなる。また、嚢胞性線維症患者の気道ではGSNOR活性が顕著に高まり、その触媒生成物GSNOのレベルが顕著に低下する。そこで、喘息および嚢胞性線維症における目的化合物1の保護作用を調査するために、本発明者らはインビトロでGSNOR活性に対する目的化合物1、N6022、N6022-1およびN6022-2の抑制効果を測定した。
糖尿病血管合併症において、血管新生の減少および血管内皮細胞透過性の増加は、局所浮腫、虚血とそれに続く潰瘍、切断を引き起こす危険因子の一つであることが知られている。糖尿病血管合併症に対する目的化合物1の治療作用を研究するために、本発明者らは細胞レベルでヒト臍帯静脈内皮細胞(HUVECs)を高グルコース(30mM)で刺激し、目的化合物1、N6022、N6022-1およびN6022-2(10nM)で24時間処理し、内皮細胞チューブ形成アッセイにより内皮細胞の血管新生能力を測定した。
大動脈瘤/大動脈解離における目的化合物1の保護作用を調査するために、本発明者らは細胞レベルでヒト大動脈平滑筋細胞(HASMC)にアンジオテンシンII(1μM)を投与し、それぞれ目的化合物1、N6022、N6022-1およびN6022-2(10nM)で24時間処理し、細胞RNAを抽出し、平滑筋細胞収縮型/合成型マーカーを検出した。
目的化合物1の経口バイオアベイラビリティを測定するために、本発明者らは、ICRマウスを用いてそれぞれ静脈注射によりN6022(1mg/kg)および目的化合物1(1.2mg/kg)を単回投与し、経口でN6022(5mg/kg)および目的化合物1(6mg/kg)を単回投与した後、0.083,0.25,0.5,1,2,4,8,24時間目にLC-MS/MSにより血中薬物濃度を測定した(図5)。
糖尿病血管合併症に対する目的化合物1の経口薬効をさらに研究するために、SPF級の8週齢雄C57BL/6Jマウス(南京医科大学医薬実験動物センターから購入)をランダムに対照群、糖尿病モデル群、糖尿病モデル+目的化合物1強制経口投与(6mg/kg/day)群、糖尿病モデル+N6022-1強制経口投与(5.6mg/kg/day)群、糖尿病モデル+N6022-2強制経口投与(5.3mg/kg/day)群、および糖尿病モデル+N6022静脈注射(1mg/kg/day)群の6群に分けた。糖尿病モデルでは、8週目にマウスにストレプトゾトシンを5日間連続して腹腔内注射し(60mg/kg/day)、10週目に血糖を測定し、血糖値が>16.6mmol/Lである場合、モデル構築が成功した。全ての群では、12週目にマウスに対して側肢虚血モデルを構築し、手術後にそれぞれ毎日N6022、目的化合物1、N6022-1およびN6022-2を投与し、それぞれ0、7、14日目にレーザースペックル血流イメージングシステムにより側肢の血流回復状況をモニタリングした(図6A)。マウスの虚血性側肢の腓腹筋を分離して凍結切片し、免疫蛍光(CD31)により血管新生の状況を調べた(図6B)。半膜様筋を分離して凍結切片し、免疫蛍光(α-SMA)により動脈形成の状況を調べた(図6B)。
大動脈瘤/大動脈解離疾患に対する目的化合物1の経口薬効をさらに研究するために、SPF級の3週齢雄C57BL/6Jマウス(南京医科大学医薬実験動物センターから購入)を用い、ランダムに対照群、疾患モデル群(0.25%β-アミノプロピオニトリル飲料水、28日)、疾患モデル+目的化合物1強制経口投与(6mg/kg/day)群、疾患モデル+N6022-1強制経口投与(5.6mg/kg/day)群、疾患モデル+N6022-2強制経口投与(5.3mg/kg/day)群、および疾患モデル+N6022静脈注射(1mg/kg/day)群の6群に分けた。結果として、単なるβ-アミノプロピオニトリル飲料水の疾患モデル群のマウスは、大動脈に明らかな病理学的拡大が発生し、上行大動脈/下行大動脈/胸部大動脈の直径が、いずれも対照群の約1.5倍であり、死亡率と大動脈解離の発生率が対照群と比較して顕著に増加したが、疾患モデル群のマウスに対して目的化合物1を強制経口投与した後、大動脈径の拡大とマウスの死亡率の両方が抑制された(図7)。
Claims (2)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011622515.7A CN112574193B (zh) | 2020-12-31 | 2020-12-31 | 一类口服gsnor抑制剂及其药物用途 |
CN202011622515.7 | 2020-12-31 | ||
PCT/CN2021/089594 WO2022141977A1 (zh) | 2020-12-31 | 2021-04-25 | 一类口服gsnor抑制剂及其药物用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2023501853A true JP2023501853A (ja) | 2023-01-20 |
Family
ID=75144614
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022505579A Pending JP2023501853A (ja) | 2020-12-31 | 2021-04-25 | 経口gsnor阻害剤およびその医薬用途 |
Country Status (7)
Country | Link |
---|---|
US (1) | US11667616B2 (ja) |
EP (1) | EP4050011B1 (ja) |
JP (1) | JP2023501853A (ja) |
KR (1) | KR102475590B1 (ja) |
CN (1) | CN112574193B (ja) |
DK (1) | DK4050011T3 (ja) |
WO (1) | WO2022141977A1 (ja) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012500216A (ja) * | 2008-08-15 | 2012-01-05 | エヌサーティー・ファーマシューティカルズ,エルエルシー | 治療薬剤としての、s−ニトロソグルタチオンレダクターゼの新規ピロール阻害剤 |
JP2014506875A (ja) * | 2010-12-16 | 2014-03-20 | エヌ30 ファーマシューティカルズ,インコーポレイテッド | S−ニトロソグルタチオンレダクターゼ阻害薬としての新規な置換二環芳香族化合物 |
US20150005352A1 (en) * | 2013-06-26 | 2015-01-01 | The Regents Of The University Of California | Reactive oxygen species-based prodrugs |
CN109943622A (zh) * | 2019-03-07 | 2019-06-28 | 南京医科大学 | 亚硝基谷胱甘肽还原酶的医药用途 |
CN109999029A (zh) * | 2019-03-07 | 2019-07-12 | 南京医科大学 | N6022在治疗糖尿病外周动脉疾病中的医药用途 |
JP2020516664A (ja) * | 2017-04-11 | 2020-06-11 | セージ ファーマ, エルエルシー | カルバゾール化合物及びその使用法 |
CN111529524A (zh) * | 2020-04-24 | 2020-08-14 | 南京医科大学 | N6022在预防和治疗主动脉夹层和主动脉瘤中的应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0100902D0 (sv) * | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
WO2009076665A1 (en) * | 2007-12-13 | 2009-06-18 | Indiana University Research And Technology Corporation | Materials and methods for inhibiting mammalian s-nitrosoglutathione reductase |
EP2318007B1 (en) | 2008-08-15 | 2013-01-23 | N30 Pharmaceuticals, Inc. | Novel pyrrole inhibitors of s-nitrosoglutathione reductase as therapeutic agents |
US20140135396A1 (en) * | 2011-07-05 | 2014-05-15 | Beth Israel Deaconess Medical Center, Inc. | Treatment of Acetaminophen-Induced Liver Damage by the Administration of Modulators of Nitric Oxide |
US10925858B2 (en) * | 2017-05-08 | 2021-02-23 | The US Government as represented by the Department of Veterans Affairs | S-nitrosoglutathione (GSNO) and GSNO reductase inhibitors for use in therapy |
-
2020
- 2020-12-31 CN CN202011622515.7A patent/CN112574193B/zh active Active
-
2021
- 2021-04-25 DK DK21847920.2T patent/DK4050011T3/da active
- 2021-04-25 KR KR1020227003378A patent/KR102475590B1/ko active IP Right Grant
- 2021-04-25 US US17/628,904 patent/US11667616B2/en active Active
- 2021-04-25 JP JP2022505579A patent/JP2023501853A/ja active Pending
- 2021-04-25 WO PCT/CN2021/089594 patent/WO2022141977A1/zh unknown
- 2021-04-25 EP EP21847920.2A patent/EP4050011B1/en active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012500216A (ja) * | 2008-08-15 | 2012-01-05 | エヌサーティー・ファーマシューティカルズ,エルエルシー | 治療薬剤としての、s−ニトロソグルタチオンレダクターゼの新規ピロール阻害剤 |
JP2014506875A (ja) * | 2010-12-16 | 2014-03-20 | エヌ30 ファーマシューティカルズ,インコーポレイテッド | S−ニトロソグルタチオンレダクターゼ阻害薬としての新規な置換二環芳香族化合物 |
US20150005352A1 (en) * | 2013-06-26 | 2015-01-01 | The Regents Of The University Of California | Reactive oxygen species-based prodrugs |
JP2020516664A (ja) * | 2017-04-11 | 2020-06-11 | セージ ファーマ, エルエルシー | カルバゾール化合物及びその使用法 |
CN109943622A (zh) * | 2019-03-07 | 2019-06-28 | 南京医科大学 | 亚硝基谷胱甘肽还原酶的医药用途 |
CN109999029A (zh) * | 2019-03-07 | 2019-07-12 | 南京医科大学 | N6022在治疗糖尿病外周动脉疾病中的医药用途 |
CN111529524A (zh) * | 2020-04-24 | 2020-08-14 | 南京医科大学 | N6022在预防和治疗主动脉夹层和主动脉瘤中的应用 |
Non-Patent Citations (1)
Title |
---|
XICHENG SUN ET AL.: "Structure-activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: Pyrrole", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. Volume 21,Issue 21, JPN6023005219, 24 April 2011 (2011-04-24), pages 3671 - 3675, ISSN: 0004989918 * |
Also Published As
Publication number | Publication date |
---|---|
EP4050011A1 (en) | 2022-08-31 |
US11667616B2 (en) | 2023-06-06 |
EP4050011B1 (en) | 2023-09-13 |
KR102475590B1 (ko) | 2022-12-08 |
US20220372007A1 (en) | 2022-11-24 |
CN112574193A (zh) | 2021-03-30 |
CN112574193B (zh) | 2022-05-17 |
WO2022141977A1 (zh) | 2022-07-07 |
KR20220098338A (ko) | 2022-07-12 |
EP4050011A4 (en) | 2022-10-12 |
DK4050011T3 (da) | 2023-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11801316B2 (en) | Cromolyn derivatives and related methods of imaging and treatment | |
US20240058480A1 (en) | Cromolyn derivatives and related methods of imaging and treatment | |
US7074826B2 (en) | R-NSAID esters and their use | |
JP4727579B2 (ja) | マロニル−CoAデカルボキシラーゼ阻害剤として有用なシアノアミド化合物 | |
US20170290797A1 (en) | Combination therapies for the treatment of alzheimer's disease and related disorders | |
ES2655455T3 (es) | Composiciones para el tratamiento de hipertensión y/o fibrosis | |
ES2268127T3 (es) | Derivados de benzazol para el tratamiento de esclerodermia. | |
JP2023501853A (ja) | 経口gsnor阻害剤およびその医薬用途 | |
KR101359936B1 (ko) | 내피 기능장애를 치료하는 약제를 수득하기 위한 이바브라딘의 용도 | |
JP2015519333A5 (ja) | ||
KR102532836B1 (ko) | 신규 프로스타글란딘 유도체 | |
JP2004250400A (ja) | ピリミジン誘導体 | |
US20220144804A1 (en) | Compound for Specifically Enhancing Spatial Coupling Degree of TRPV4-KCa2.3 Complex and Use thereof | |
WO2019159868A1 (ja) | 大腸炎改善剤 | |
JPH0376302B2 (ja) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220127 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20220127 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230214 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230428 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230630 |